RGLS Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Regulus Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.49 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$1.08 |
| Beta | 1.6 |
| 1 Month Change | -12.35% |
| 3 Month Change | -1.97% |
| 1 Year Change | 14.62% |
| 3 Year Change | -39.70% |
| 5 Year Change | -87.69% |
| Change since IPO | -99.70% |
Recent News & Updates
Recent updates
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Sep 28
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Shareholder Returns
| RGLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.5% | -0.1% | -0.5% |
| 1Y | 14.6% | -6.4% | 23.2% |
Return vs Industry: RGLS exceeded the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: RGLS underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| RGLS volatility | |
|---|---|
| RGLS Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RGLS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RGLS's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 32 | Jay Hagan | www.regulusrx.com |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. Fundamentals Summary
| RGLS fundamental statistics | |
|---|---|
| Market cap | US$97.60m |
| Earnings (TTM) | -US$41.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs RGLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGLS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$22.62m |
| Gross Profit | -US$22.62m |
| Other Expenses | US$19.01m |
| Earnings | -US$41.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RGLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 20:43 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets U.S. (Historical) |
| Madhu Kumar | B. Riley Securities, Inc. |